CNN reported on Friday that the US Food and Drug Administration authorised a new test that diagnoses both influenza and for COVID-19, CNN reported on Friday.
The test, designed by the US Centers for Disease Control and Prevention (CDC), is the first dual test to get emergency use authorisation from the FDA.
FDA Commissioner Stephen Hahn was quoted as saying in a statement:
"With the authorisation of these tests, the FDA is helping address concerns in anticipation of this upcoming flu season during the COVID-19 pandemic, which might be especially worrying for some Americans."
"With just one swab or sample, combination tests can be used to get answers to Americans faster. This efficiency can go a long way to providing timely information for those sick with an unknown respiratory ailment," Hahn added.
AstraZeneca's tozorakimab meets primary endpoints in two Phase III COPD trials
Eisai and Nuvation Bio report taletrectinib MAA validated by European regulator
Akeso's Phase II trials of AK146D1 and AK138D1 approved in China
Roche launches new test to help clinicians treat patients with respiratory infections
GSK secures Japan Orphan Drug status for lung cancer ADC
Dizal meets primary endpoint in Phase 3 study of ZEGFROVY (sunvozertinib) monotherapy
bioMérieux secures IVDR CE marking for respiratory diagnostic panels in Europe
IDEAYA Biosciences enrols first patient in Phase 1 trial of PRMT5 inhibitor IDE892
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation
Novartis to build new radioligand therapy site in Texas
GSK to acquire 35Pharma for USD950m to strengthen cardiopulmonary pipeline